NVCT — Nuvectis Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875558 ·
Last close
$20.22
Market Cap
$660.06M
52W High
$29.27
52W Low
$5.55
ADV30
217,403
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -7,197,000 | -7,020,000 | 22,376,000 | 22,160,000 | 13,294,000 |
| Mar 2026 | 0 | — | -6,260,000 | -6,050,000 | 25,398,000 | 25,130,000 | 11,178,000 |
| Dec 2025 | 0 | — | -7,617,000 | -7,314,000 | 31,709,000 | 31,634,000 | 13,296,000 |
| Sep 2025 | 0 | — | -7,794,000 | -7,462,000 | 35,587,000 | 35,442,000 | 11,577,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,510,000
Investing CF
$0
Financing CF
$14,877,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.30
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-112,757,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-28,868,000
Pretax Income TTM
$-27,846,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,574,000 | -26,442,000 | 31,709,000 | 13,296,000 | 18,413,000 | -16,009,000 |
| Dec 2024 | 0 | -19,847,000 | -19,000,000 | 18,607,000 | 8,894,000 | 9,713,000 | -12,247,000 |
| Dec 2023 | 0 | -22,897,000 | -22,260,000 | 19,185,000 | 6,984,000 | 12,201,000 | -15,954,000 |
| Dec 2022 | 0 | -19,234,000 | -19,085,000 | 20,405,000 | 6,186,000 | 14,219,000 | -13,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.96
Max Pain — expiry 2026-10-16
max pain strike: $15.00 · spot: $20.56 · call oi: 4,846 · put oi: 104
Expected Move to 2026-10-16:
±$2.90
(14.11%) —
implied range
$17.66 –
$23.46
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVRA | ZEVRA THERAPEUTICS, INC. | $655.60M | $11.04 | — |
| CLYM | Climb Bio, Inc. | $669.71M | $11.66 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $682.44M | $4.13 | — |
| ANNX | Annexon, Inc. | $690.07M | $3.64 | — |
| SLN | Silence Therapeutics plc | $694.88M | $11.18 | — |
News headlines (Yahoo Finance, 1h cache)
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
2026-09-24 12:00 · Yahoo
Nuvectis Pharma To Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
2026-08-19 15:33 · Yahoo
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
2026-07-14 14:40 · Yahoo
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
2026-07-08 13:55 · Yahoo
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)
2026-06-30 12:36 · Yahoo
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
2026-06-30 02:30 · Yahoo
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
2026-06-26 16:00 · Yahoo
Haisco and Nuvectis sign licensing deal for two drugs
2026-06-24 09:10 · Yahoo
Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)
2026-06-22 12:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.